EDMONTON, Alberta, Jan. 3, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) (“Isotechnika” or the “Company”) is pleased to announce that it has signed a Global Development and Commercialization License agreement with Vifor Pharma Ltd., the specialty pharma company of Switzerland based Galenica Group. The agreement grants Vifor Pharma an exclusive license for the Company’s lead drug, voclosporin, for the treatment of lupus and all proteinuric nephrology indications (the “Vifor Pharma License”). The Vifor Pharma License is for the United States and other regions outside of Canada, South Africa, Israel, China, Taiwan and Hong Kong (the “Vifor Pharma Territory”). While the details of the transaction are confidential, Isotechnika noted that it is eligible to receive significant upfront and milestone payments, as well as royalties on commercial sales. In connection with this agreement, Vifor Pharma will be purchasing voclosporin capsules from Isotechnika.
